324 related articles for article (PubMed ID: 31578912)
1. Risankizumab in moderate-to-severe plaque psoriasis.
Serrano L; Maloney V; Gordon KB
Immunotherapy; 2019 Nov; 11(16):1357-1370. PubMed ID: 31578912
[TBL] [Abstract][Full Text] [Related]
2. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
3. Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature.
McDonald J; Maliyar K; Gooderham MJ
Skin Therapy Lett; 2020 May; 25(3):1-4. PubMed ID: 32510689
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab.rzaa: an interleukin monoclonal antibody antagonist binding to the p19 subunit of human IL-23 cytokine.
Paton DM
Drugs Today (Barc); 2019 Oct; 55(10):605-613. PubMed ID: 31720558
[TBL] [Abstract][Full Text] [Related]
5. Update on risankizumab for the treatment of moderate to severe psoriasis.
Al-Janabi A; Warren RB
Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial.
Ohtsuki M; Fujita H; Watanabe M; Suzaki K; Flack M; Huang X; Kitamura S; Valdes J; Igarashi A
J Dermatol; 2019 Aug; 46(8):686-694. PubMed ID: 31237727
[TBL] [Abstract][Full Text] [Related]
8. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
9. A drug safety evaluation of risankizumab for psoriasis.
Huang YW; Tsai TF
Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
[No Abstract] [Full Text] [Related]
10. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
[TBL] [Abstract][Full Text] [Related]
11. Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Jul; 54(7):433-444. PubMed ID: 30090880
[TBL] [Abstract][Full Text] [Related]
12. Risankizumab for the treatment of moderate to severe psoriasis.
Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
[No Abstract] [Full Text] [Related]
13. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
14. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.
Xu S; Zhang X; Pan M; Shuai Z; Xu S; Pan F
Int Immunopharmacol; 2019 Oct; 75():105841. PubMed ID: 31465912
[TBL] [Abstract][Full Text] [Related]
15. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ; Warren RB; Cather JC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
Ruggiero A; Fabbrocini G; Cinelli E; Ocampo Garza SS; Camela E; Megna M
Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
[TBL] [Abstract][Full Text] [Related]
17. Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.
Blauvelt A; Chiricozzi A; Ehst BD; Lebwohl MG
Adv Ther; 2023 Aug; 40(8):3410-3433. PubMed ID: 37330926
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab for the Treatment of Psoriasis.
Machado Á; Torres T
BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
[TBL] [Abstract][Full Text] [Related]
19. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
[TBL] [Abstract][Full Text] [Related]
20. Tildrakizumab for the treatment of psoriasis.
Bangert C; Kopp T
Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]